首页/数据集/NSCLC cell lines with acquired resistance to afatinib + cetuximab. Homo sapiens

NSCLC cell lines with acquired resistance to afatinib + cetuximab. Homo sapiens

NIAID Data Ecosystem2026-03-09 收录

EGFR突变肺癌耐药机制

肿瘤细胞系药物敏感性

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA264974 数据链接链接失效反馈

官方服务：

资源简介：

Understanding mechanisms of acquired resistance to afatinib +cetuximab in EGFR-mutant lung cancer

应用场景：

创建时间：

2014-10-27

EGFR突变肺癌耐药机制

"RNA研究"

EGFR inhibitors (EGFRi) are effective against EGFR mutant lung cancers. The efficacy of these drugs however is mitigated by the outgrowth of resistant cells, most often driven by a secondary acquired

NIAID Data Ecosystem70

Integrative Profiling of T790M Negative EGFR Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities

EGFR突变肺癌耐药机制

肿瘤免疫微环境分析

We performed whole exome and transcriptome analysis of 59 first- and second-generation EGFR TKI resistant metastatic EGFR mutated patients to characterize and compare molecular alterations mediating r

NIAID Data Ecosystem40

Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

EGFRT790M抑制剂

肿瘤细胞系药物敏感性

XLSX file - 109K, Tumor cell line profiling of G�6976 sensitivity.

NIAID Data Ecosystem20

Inactivation of the splicing factor RBM10 limits EGFR targeted therapy response in EGFR mutant lung cancer

EGFR突变肺癌耐药机制

RNA靶向治疗

Oncogene-driven lung cancers such as those with activating mutations in the epidermal growth factor receptor (EGFR) often harbor additional co-occurring genetic alterations. The significance of most a

NIAID Data Ecosystem50

Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

EGFRT790M抑制剂筛选

肿瘤细胞系药物敏感性

XLSX file - 109K, Tumor cell line profiling of G�6976 sensitivity.

Figshare2013-02-01 更新30